Researchers debate best use of stem cell transplants in patients with multiple myeloma.
Rowan
Karen
K
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D006801:Humans; D000077269:Lenalidomide; D008558:Melphalan / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000601:surgery*; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction / Q000379:methods; D033581:Stem Cell Transplantation; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D014182:Transplantation, Autologous; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D013792:Thalidomide; D000077269:Lenalidomide; D008558:Melphalan